Table 2 Frequencies of eligible candidates for clinical trial screening by diagnosis and sex
From: The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
Diagnosis—gender (N) | Age | Comorbidity | Medication | MMSE | Education | All criteria |
|---|---|---|---|---|---|---|
All (9593) | 7874 (82%)* | 3791 (40%)* | 6150 (64%) | 9269 (97%) | 5789 (60%) * | 1458 (15%)* |
 Men (2926) | 2480 (85%) | 1106 (38%) | 1925 (66%) | 2846 (97%) | 2144 (73%) | 506 (17%) |
 Women (6667) | 5394 (81%) | 2685 (40%) | 4225 (63%) | 6423 (96%) | 3645 (55%) | 952 (14%) |
 OR [95%CI] | 1.22 [1.08–1.37] | 0.86 [0.78–0.94] | 1.08 [0.98–1.19] | 1.09 [0.84–1.42] | 2.25 [2.05–2.48] | 1.26 [1.12–1.41] |
AD (5278) | 3875 (73%)* | 2106 (40%)* | 3222 (61%) | 4973 (94%) | 2792 (53%) * | 623 (12%)* |
 Men (1466) | 1122 (77%) | 563 (38%) | 899 (61%) | 1393 (95%) | 984 (67%) | 208 (14%) |
 Women (3812) | 2753 (72%) | 1543 (40%) | 2.323 (61%) | 3580 (94%) | 1808 (47%) | 415 (11%) |
 OR [95%CI] | 1.22 [1.06–1.41] | 0.87 [0.77–0.99] | 0.98 [0.86–1.11] | 1.07 [0.81–1.41] | 2.26 [1.99–2.57] | 1.35 [1.13–1.62] |
MCI (4,315) | 3999 (93%) | 1685 (39%)* | 2928 (68%)* | 4296 (100%) | 2997 (69%) * | 835 (19%) |
 Men (1,460) | 1358 (93%) | 543 (37%) | 1026 (70%) | 1453 (100%) | 1160 (79%) | 298 (20%) |
 Women (2,855) | 2641 (93%) | 1142 (40%) | 1902 (67%) | 2843 (100%) | 1837 (64%) | 537 (19%) |
 OR [95%CI] | 1.05 [0.82–1.34] | 0.85 [0.74–0.97] | 1.19 [1.04–1.37] | 0.81 [0.31–2.11] | 2.15 [1.85–2.49] | 1.11 [0.95–1.30] |